Bioengineered tissues in wound healing: A progress report

Expert Review of Dermatology

Volumn 6, Issue 3, 2011, Pages 255-262

  Lepow, Brian D ^a,b   Downey, Michael ^c   Yurgelon, Jesse ^c   Klassen, Lindsey ^c   Armstrong, David G ^a,b  

^a UNIVERSITY OF ARIZONA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c MIDWESTERN UNIVERSITY   (United States)

Author keywords

bioengineered skin substitutes; biologics; chronic ulceration; diabetes; wound care; wound healing; wounds

Indexed keywords

BOVINE COLLAGEN; BOVINE COLLAGEN TYPE 1; CHONDROITIN 6 SULFATE; COLLAGEN; ELASTIN; GLYCOSAMINOGLYCAN; GROWTH FACTOR; HYALURONIC ACID; MATRIX PROTEIN; NYLON; POLYGLACTIN; SILICONE; SULFADIAZINE SILVER; TISSUE SCAFFOLD; TYPE 1 PORCINE COLLAGEN; UNCLASSIFIED DRUG;

ALLOGRAFT; AUTOGRAFT; BASEMENT MEMBRANE; BIODEGRADABILITY; BIOENGINEERED SKIN SUBSTITUTE; BIOENGINEERING; BURN; CHRONIC WOUND; COMPOSITE MATERIAL; CULTURED EPIDERMAL GRAFT; DISEASE TRANSMISSION; EPIDERMAL GRAFT; EXTRACELLULAR MATRIX; FOOT ULCER; GAMMA IRRADIATION; GRAFT REJECTION; HUMAN; KERATINOCYTE; LEG ULCER; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; SCAR FORMATION; SHELF LIFE; SKIN FIBROBLAST; SKIN GRAFT; SPLIT THICKNESS SKIN GRAFT; TISSUE CULTURE; TISSUE GRAFT; WOUND; WOUND HEALING;

EID: 79958196443     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/edm.11.27     Document Type: Review

References (47)

1. Metcalfe AD, Ferguson MW. Tissue engineering of replacement skin: the crossroads of biomaterials, wound healing, embryonic development, stem cells and regeneration. J. R. Soc. Interface 4(14), 413-437 (2007).
2. Schilling JA. Wound healing. Surg. Clin. North Am. 56(4), 859-874 (1976).
3. Broughton G 2nd, Janis JE, Attinger CE. The basic science of wound healing. Plast. Reconstr. Surg. 117(Suppl. 7), S12-S34 (2006).
4. Yager DR, Nwomeh BC. The proteolytic environment of chronic wounds. Wound Repair Regen. 7(6), 433-441 (1999). (Pubitemid 30027565)
5. Witte MB, Barbul A. Role of nitric oxide in wound repair. Am. J. Surg. 83(4), 406-412 (2002). (Pubitemid 34442505)
6. Schreml S, Szeimies RM, Prantl L, Landthaler M, Babilas P. Wound healing in the 21st Century. J. Am. Acad. Dermatol. 63(5), 866-881 (2010).
7. Sabiston D. The Biological Basis of Modern Surgical Practice (15th Edition). Saunders, St Louis, MO, USA (1997).
8. Loots MA, Lamme EN, Zeegelaar J, Mekkes JR, Bos JD, Middelkoop E. Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. J. Invest. Dermatol. 111(5), 850-857 (1998). (Pubitemid 28509329)
9. Lazarus GS, Cooper DM, Knighton DR, et al. Definitions and guidelines for assessment of wounds and evaluation of healing. Arch. Dermatol. 130(4), 489-493 (1994). (Pubitemid 24123372)
10. Hehenberger K, Heilborn JD, Brismar K, Hansson A. Inhibited proliferation of fibroblasts derived from chronic diabetic wounds and normal dermal fibroblasts treated with high glucose is associated with increased formation of l-lactate. Wound Repair Regen. 6(2), 135-141 (1998). (Pubitemid 128659189)
11. Attinger CE, Janis JE, Steinberg J, Schwartz J, Al-Attar A, Couch K. Clinical approach to wounds: debridement and wound bed preparation including the use of dressings and wound-healing adjuvants. Plast. Reconstr. Surg. 117(Suppl. 7), S72-S109 (2006).
12. Kim PJ, Heilala M, Steinberg JS, Weinraub GM. Bioengineered alternative tissues and hyperbaric oxygen in lower extremity wound healing. Clin. Podiatr. Med. Surg. 24(3), 529-546, x (2007). (Pubitemid 47018237)
13. Brem H, Balledux J, Sukkarieh T, Carson P, Falanga V. Healing of venous ulcers of long duration with a bilayered living skin substitute: results from a general surgery and dermatology department. Dermatol. Surg. 27(11), 915-919 (2001). (Pubitemid 33101645)
14. Veves A, Falanga V, Armstrong DG, Sabolinski ML. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 24(2), 290-295 (2001). (Pubitemid 32119127)
15. Sheehan P, Jones P, Giurini JM, Caselli A, Veves A. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Plast. Reconstr. Surg. 117(7 Suppl.), 239S-244S (2006). (Pubitemid 44317787)
16. Redekop W, McDonnell J, Verboom P, Lovas K, Kalo Z. The cost effectiveness of Apligraft treatment of diabetic foot ulcers. Pharmacoeconomics 21(16), 1171-1183 (2003). (Pubitemid 37463826)
17. Fivenson D, Scherschun L. Clinical and economic impact of Apligraf for the treatment of nonhealing venous leg ulcers. Int. J. Dermatol. 42(12), 960-965 (2003). (Pubitemid 38004472)
18. Kim PJ, Dybowski KS, Steinberg JS. A closer look at bioengineered alternative tissues. Podiatry Today 19(7) 38-55 (2006).
19. Bello YM, Falabella AF, Eaglstein WH. Tissue-engineered skin. Current status in wound healing. Am. J. Clin. Dermatol. 2(5), 305-313 (2001). (Pubitemid 33027822)
20. Pollak R, Edington H, Jensen J. A human dermal replacement for the treatment of diabetic foot ulcers. Wounds 9, 175-183 (1997). (Pubitemid 127580015)
21. Hansbrough JF. Status of cultured skin replacement. Wounds 4(7), 130-136 (1995).
22. Ruszczak Z. Effect of collagen matrices on dermal wound healing. Adv. Drug Deliv. Rev. 55(12), 1595-1611 (2003). (Pubitemid 37412595)
23. Monami M, Vivarelli M, Desideri CM, Ippolito G, Marchionni N, Mannucci E. Autologous skin fibroblast and keratinocyte grafts in the treatment of chronic foot ulcers in aging Type 2 diabetic patients. J. Am. Podiatr. Med. Assoc. 101(1), 55-58 (2011).
24. Greenberg JE, Falabella AF, Bello YM, Schachner LA. Tissue-engineered skin in the healing of wound stumps from limb amputations secondary to purpura fulminans. Pediatr. Dermatol. 20(2), 169-172 (2003)
25. Morgan JR, Yarmush M. Bioengineered skin substitutes. Sci. Med. 4, 6-15 (1997).
26. Iorio ML, Goldstein J, Adams M, Steinberg J, Attinger C. Functional limb salvage in the diabetic patient: the use of a collagen bilayer matrix and risk factors for amputation. Plast. Reconstr. Surg. 127(1), 260-267 (2011).
27. Violas P, Abid A, Darodes P, Galinier P, de Gauzy JS, Cahuzac JP. Integra artificial skin in the management of severe tissue defects, including bone exposure, in injured children. J. Pediatr. Orthop. B 14(5), 381-384 (2005). (Pubitemid 41291468)
28. Burke J, Yannas IV, Quinby WC. Successful use of physiologically acceptable artificial skin in the treatment of extensive burn injury. Ann. Surg. 194, 413-428 (1981).
29. Pham C, Greenwood J, Cleland H, Woodruff P, Maddern G. Bioengineered skin substitutes for the management of burns: a systematic review. Burns 33(8), 946-957 (2007). (Pubitemid 350051194)
30. Dantzer E, Braye FM. Reconstructive surgery using an artificial dermis (Integra): results with 39 grafts. Br. J. Plast. Surg. 54(8), 659-664 (2001). (Pubitemid 33150027)
31. Heimbach DM, Warden GD, Luterman A, et al. Multicenter postapproval clinical trial of Integra dermal regeneration template for burn treatment. J. Burn Care Rehabil. 24(1), 42-48 (2003). (Pubitemid 36152561)
32. Gomez ER, Rosenthal D. Management of a subcutaneous colostomy perforation. The role of a new synthetic skin. Dis. Colon Rectum 27(10), 651-653 (1984). (Pubitemid 14014016)
33. Whitaker IS, Prowse S, Potokar TS. A critical evaluation of the use of Biobrane as a biologic skin substitute: a versatile tool for the plastic and reconstructive surgeon. Ann. Plast. Surg. 60(3), 333-337 (2008).
34. Kirwan L. Management of difficult wounds with Biobrane. Conn. Med. 59(9), 523-529 (1995).
35. Demling RH. Use of Biobrane in management of scalds. J. Burn Care Rehabil. 16(3 Pt 1), 329-330 (1995).
36. Brown-Etris M, Cutshall W, Hiles MC. A new biomaterial derived from small intestine submucosa and developed into wound matrix device. Wounds 14, 150-166 (2002). (Pubitemid 41505207)
37. Mostow EN, Haraway GD, Dalsing M, Hodde JP, King D. Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. J. Vasc. Surg. 41(5), 837-843 (2005). (Pubitemid 40693807)
38. Winters CL, Brigido SA, Liden BA, Simmons M, Hartman JF, Wright ML. A multicenter study involving the use of a human acellular dermal regenerative tissue matrix for the treatment of diabetic lower extremity wounds. Adv. Skin Wound Care 21(8), 375-381 (2008).
39. Rosales MA, Bruntz M, Armstrong DG. g-irradiated human skin allograft: a potential treatment modality for lower extremity ulcers. Int. Wound J. 1(3), 201-206 (2004).
40. Reyzelman A, Crews RT, Moore JC, et al. Clinical effectiveness of an acellular dermal regenerative tissue matrix compared to standard wound management in healing diabetic foot ulcers: a prospective, randomised, multicentre study. Int. Wound J. 6(3), 196-208 (2009).
41. Brigido SA. The use of an acellular dermal regenerative tissue matrix in the treatment of lower extremity wounds: a prospective 16-week pilot study. Int. Wound J. 3(3), 181-187 (2006).
42. Purdue GF, Hunt JL, Still JM Jr, et al. A multicenter clinical trial of a biosynthetic skin replacement, Dermagraft-TC, compared with cryopreserved human cadaver skin for temporary coverage of excised burn wounds. J. Burn Care Rehabil. 18(1 Pt 1), 52-57 (1997). (Pubitemid 27108223)
43. Scimeca CL, Bharara M, Fisher TK, Kimbriel H, Mills JL, Armstrong DG. An update on pharmacological interventions for diabetic foot ulcers. Foot Ankle Spec. 3(5), 285-302 (2010).
44. Armstrong DG, Giovinco NA. Diagnostics, theragnostics, and the personal health server: fundamental milestones in technology with revolutionary changes in diabetic foot and wound care to come. Foot Ankle Spec. 4(1), 54-60 (2011).
45. Gabriel A, Mussman J. Wound healing, growth factors. May 2009 http://emedicine.medscape.com/ article/1298196-overview
46. Promethean LifeSciences, Inc. GammaGraft www.pl-s.com/gammagraft.html
47. Valenza T. New technology for tissue regeneration derived from sheep (2009) www.plasticsurgerypractice.com/issues/ articles/2009-10-08.asp